- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Migraine
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 OOS August 2023 PBAC Meeting - (PDF 836KB)
- Public Summary Document (PSD) November OOS August 2023 2022 PBAC Meeting - (Word 149KB)
Fremanezumab – November 2022
FREMANEZUMAB: Solution for injection 225 mg in 1.5 mL single dose pre-filled syringe, Solution for injection 225 mg in 1.5 mL single dose autoinjector; Ajovy® - November 2022 – OOS August 2023 PBAC Meetings
Last updated
27 October 2023